China 
Africa 
Explore chapters and articles related to this topic
Haemopoietic Stem Cell Transplantation for Rheumatoid Arthritis—World Experience and Future Trials
Published in Richard K. Burt, Alberto M. Marmont, Stem Cell Therapy for Autoimmune Disease, 2019
John A. Snowden, John J. Moore, Sarah J. Bingham, Steve Z. Pavletic, Richard K. Burt
In contrast to using myeloablative regimens with their attendant risks, it may be reasonable to accept that, in the interests of safety, that dose intensification of cytotoxic therapy should not increase significantly and that other strategies should be considered. High dose cyclophosphamide 200 mg/kg, which has been shown to be relatively safe and produce profound responses, at least in the short term, might be best regarded as a form of ‘remission induction’ or ‘debulking’ therapy, but, as suggested by the study of Bingham et al,44 leaving ‘minimal residual disease’. Using this regimen, there seems to be no major clinical benefit to be gained from CD34 purification and lymphocyte depletion for RA.38 However, there is now a body of data, albeit uncontrolled, to support increased disease control by the re-introduction of disease modifying agents. In most instances, disease modifying agents have been re-introduced at a time of relapse. By logical extension, given that disease activity is not completely eradicated in the majority of patients, it would seem reasonable to introduce such treatment immediately post-transplant as maintenance treatment.52 This approach is analogous to that of low grade lymphoproliferative disorders, such as myeloma and follicular lymphoma, which are incurable but are routinely treated with autologous transplant with the aim of inducing profound remissions. Disease progression may be delayed further with the use of maintenance agents such as interferon or thalidomide.
Accurate demarcation of a biased nucleus from H&E-stained follicular lymphoma tissues samples
Published in The Imaging Science Journal, 2023
Cancer is a collection of diseases that can invade and spread to different body parts and is defined by abnormal cell proliferation. It is a fatal illness that affects people all across the world, not just in India. Only in the United States, it was predicted that there would be 6,09,360 cancer fatalities and 19,18,030 new cases of cancer (including all varieties) in 2022 [1]. Across all sites, men have a 40% higher cancer death rate and a 20% higher cancer incidence rate than women [1]. Lymphomas are white blood cell cancer that starts in infecting-fighting cells of the immune system, known as lymphocytes. These lymphomas can be divided mostly into two groups. Hodgkins lymphoma (HL), which verifies the existence of Reed-Sternberg cells, comes first (giant cells found with light microscopy). Non-Hodgkins lymphoma (NHL), which excludes Reed-Sternberg cells, is a different classification. Since it is hard to study and examine every type of cancer under one heading, this study focuses on a subtype of non-Hodgkins lymphoma named follicular lymphoma (FL).
Analysis of Proposed and Traditional Boosting Algorithm with Standalone Classification Methods for Classifying Gene Expresssion Microarray Data Using a Reject Option
Published in Applied Artificial Intelligence, 2022
Adil Aslam Mir, Lal Hussain, Muhammad Hammad Waseem, Amjad Aldweesh, Saim Rasheed, El Sayed Yousef, Malik Sajjad Ahmed Nadeem, Elsayed Tag Eldin
In this analysis, the gene expression microarray data of lymphoid cancer (Shipp et al. 2002) is used. This dataset contains data about the patients of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients. The dataset contains information for 58 DLBCL patients and 19 FL patients. For analysis, we split our dataset into train and test sets in such a way that the test set is independent of the train set as mentioned above.